Prozinc Vial

ProZinc is a protamine zinc insulin prescribed by veterinarians to help support the insulin levels of diabetic cats and dogs. It typically effects your pet for 10-14 hours at a time, which helps to keep their blood glucose level consistent throughout the day. It contains recombinant DNA that mimics human insulin, so it helps to control your pet’s diabetic symptoms and keeps them comfortable.

Key Ingredients:

• Insulin
• Protamine Sulfate
• Zinc Oxide
• Glycerin
• Dibasic Sodium Phosphate
• Heptahydrate Phenol (added as a preservative)
• Hydrochloric Acid. Water for Injection (maximum)

Key Benefits:

• PROZINC (protamine zinc recombinant human insulin) is an injectable insulin for cats and dogs.
• PROZINC is an aqueous suspension of protamine zinc recombinant human insulin that is indicated to reduce hyperglycemia (high blood glucose or high blood sugar) and clinical signs associated with hyperglycemia in cats and dogs with diabetes mellitus.

Directions For Use:

• Use of a syringe other than a u-40 syringe will result in incorrect dosing.
• For subcutaneous injection only.
• Do not shake or agitate the vial.
• Prozinc should be mixed by gently rolling the vial prior to withdrawing each dose from the vial. Once mixed, prozinc suspension has a white, cloudy appearance. Clumps or visible white particles can form in insulin suspensions: do not use the product if clumps or visible white particles persist after gently rolling the vial.
• Using a u-40 insulin syringe, the injection should be administered subcutaneously on the back of the neck or on the side of the cat.
• Always provide the client information sheet with each prescription.
• The initial recommended prozinc dose is 0.1 – 0.3 iu insulin/pound of body weight (0.2 – 0.7 iu/kg) every 12 hours. The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the cat at appropriate intervals and adjust the dose based on both clinical signs and glucose nadirs until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 150 mg/dl and clinical signs of hyperglycemia such as polyuria, polydipsia, and weight loss were improved.
• Further adjustments in the dosage may be necessary with changes in the cat’s diet, body weight, or concomitant medication, or if the cat develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

Safety Information:

• Cats presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death.
• Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
• The safety and effectiveness of PROZINC in breeding, pregnant, and lactating cats has not been evaluated.
• The safety and effectiveness of PROZINC in kittens has not been evaluated.